ESTRO 37 Abstract book

ESTRO 37

S611

handed out at the beginning of their radiation treatment. Data was retrieved between September 1st 2016 and January 1st 2017. From the questionnaire, we wanted to retrieve information about; a) age of child(ren), b) additional treatment, c) whether or not they found 'De gode strålene” helpful, d) if the book has led to discussions about their diagnosis or other aspects, e) curative or palliative intention with the treatment. In addition to answering the questions, the patients were encouraged to elaborate on some of the topics. Results The study included 72 children as next of kin. By January 1st 2017 there were 40 respondents in total. The results from the questionnaire were; a) age of children ranged from 2 to 18 years. b) 38 received additional treatment. c) 97 % of the respondents found 'De gode strålene” both helpful and informative and would recommend it to others in the same situation. Some of the respondents expressed that they could have benefitted from the book at an earlier stage of their treatment. d) 75 % found that the book contributed when they talked about radiation therapy with children. 48% responded that the book helped them communicate with school/friends, and 57% found the book helpful in their communication with family members. e) 29 of the respondents were treated with curable intention, 9 with palliative intention and 2 not applicable. No differences between the groups were found. Conclusion To be able to draw conclusions for different age groups in question c) and d), we have to distinguish between children at different age for patients with more than one child. Since 97 % of the respondents found 'De gode strålene” both helpful and informative, we can now recommend the book to different radiation departments in Norway. However, it would be useful with an extensive study to find more significant differences in our data, which includes both parents and grandparents of children as next of kin in several radiation departments in Norway. G. Marvaso 1 , G. Fanetti 1 , C. Fodor 2 , R. Ricotti 2 , D. Ciardo 2 , G. Riva 2 , S. Volpe 2 , D. Rojas 2 , D. Zerini 2 , P. Romanelli 2 , R. Cambria 2 , F. Pansini 2 , B.A. Jereczek-Fossa 3 1 Istituto Europeo di Oncologia Milano, radiation oncologist, Milan, Italy 2 Istituto Europeo di Oncologia Milano, Radiotherapy, Milan, Italy 3 Istituto Europeo di Oncologia Milano/University of Milan, Radiotherapy, Milan, Italy Purpose or Objective The focus on toxicity outcomes and Quality of Life (QoL) when evaluating contemporary methods of treating PO-1084 Short-term RT for early PCa with concomitant boost to the DIL : QoL after the end of the accrual.

prostate cancer has been increasing, especially for extreme hypofractionated RT. The aim of this first report is to examine the preliminary data and focus the attention on the acute effects of the treatment on urinary toxicity, sexual function and their impact on QoL. Material and Methods We examinated patient-reported outcomes among 65 pts in the AIRC-IG-13218 trial who completed questionnaires before diagnosis, at the end of RT and 1 months after treatment. Patients fulfilled validated measures that assessed urinary, sexual function and specific effects on quality of life, anxiety and depression, and general health with International Prostate Symptom Score (IPSS), International Index of Erectile Function – 5 (IIEF-5) and QLQ-C30. Results We completed the accrual of the planned 65 patients affected with early localized prostate cancer and treated with extreme hypofractionated RT at Our Institution between June 2015 to May 2017. The whole prostate is treated to a dose of 36.25 Gy in 5 fractions (7.25 Gy/fraction) whereas the dominant lesion (DIL) receives a simultaneous integrated boost of 37.5 Gy in 5 fractions (7.5 Gy/fraction). Median age, iPSA, and GS were as follow: 74 yrs (range 52.2-82.5 yrs) , 6.39 ng/ml (range 1.1-25), 6 (range 6-7) respectively. NCCN risk categories were represented as follow: low 13 (20%) of pts, intermediate 52 (80%). At the time of this analysis the available data concern the 60 pts who completed the RT course. Median IPSS score was 5.5, 7 and 8 at baseline, at the end of RT and after 1 months, respectively. Median IIEF was 14.5, 6 and 7.5 at baseline, at the end of RT and after 1 months, respectively. Quality of life was was 83.7%, 78.3% and 80.3% at baseline, at the end of RT and after 1 months, respectively (Table 1). Conclusion The analysis of data is still ongoing. This preliminary assessment showed that despite the moderate worsening of urinary and sexual function quality of life remain substantially stable during the first month follow up with a trend in improving one month after RT. The observed acute toxicities are predictable and in line with reported effects of short course RT. Further analysis will be warranted to evaluate persistence or improvement in terms of symptoms and quality of life scores. PO-1085 Tomotherapy of pediatric sarcomas: Outcome and toxicity rates K.A. Kessel 1,2 , M.E. Salfelder 1 , U. Thiel 3 , G. Habl 1 , S. Burdach 3 , S. Kampfer 1 , S.E. Combs 1,2 1 Technical University of Munich TUM, Department of Radiation Oncology, Munich, Germany 3 Technical University of Munich TUM - Kinderklinik Schwabing, Department of Pediatrics and Children's Cancer Research Center, Munich, Germany Purpose or Objective Radiotherapy (RT) is persistently gaining significance in treatment of pediatric tumors. Yet individual features of a growing body and multifocal stages of pediatric malignancies complicate this therapeutic approach. Helical intensity-modulated RT (tomotherapy) hits multiple targets in one session and offers a treatment with a low-risk of side effects by reducing the exposed healthy tissue. The aim of this study is to report toxicity rates, outcome and radiation characteristics. 2 Institute for innovative Radiotherapy iRT, Helmholzzentrum, Neuherberg, Germany